Sai Parenteral is set to launch its initial public offering (IPO) to raise almost Rs 410 crore from the primary market. Ahead of its opening on March 24, the grey market premium (GMP) for the pharmaceutical formulation company indicated a flat listing.
Investors who want to bid for shares in the IPO must check the following details before making an investment call.
Sai Parenteral IPO GMP Today
According to InvestorGain, the GMP for the Sai Parenteral IPO was nil on March. 24. It indicates a flat listing for the offer.
Note: GMP does not represent official data and is based on speculation.
ALSO READ: Flipkart Group CFO Sriram Venkataraman Steps Down As IPO Plans Gain Pace
Sai Parenteral IPO: Key Details
The Sai Parenteral IPO is a book-built issue of Rs 408.79 crore. It comprises a fresh issue of 73 lakh shares worth Rs 285 crore and an offer-for-sale (OFS) of 32 lakh shares amounting to Rs 123.79 crore.
The price band for the IPO is set between Rs 372 and Rs 392 per share.
To participate in the IPO, retail investors need to bid for a single lot size of 38 shares, requiring an investment of Rs 14,896. Small Non-Institutional Investors need to bid for 14 lots, amounting to an investment of Rs 2,08,544. Big Non-Institutional Investors can participate in the IPO by bidding for a minimum of 68 lots that requires an investment of Rs 10,12,928.
Arihant Capital Markets Ltd. is the book-running lead manager and Bigshare Services Ltd. is the registrar of the issue.
The subscription window will be open from March 24 to March 27, with the allotment expected to be finalised on March 30. The company will transfer shares to the demat accounts of successful bidders on April 1, and refunds to non-allottees will be done on the same day.
The shares of the company are scheduled to list on the BSE and NSE on April 2.
ALSO READ: IPOs This Week: Powerica, Sai Parenteral's Among Six Issues Opening For Bidding
Use Of Proceeds
The company will use proceeds from the IPO for capacity expansion and upgradation of manufacturing facilities, establishment of a research and development (R&D) centre, clearing debt, meeting working capital requirements, investing in its wholly owned subsidiary, and for general corporate purposes.
About Sai Parenteral - Business And Financials
Sai Parenterals operates as a diversified pharmaceutical formulations firm, with capabilities spanning research, development and manufacturing. Its business is structured around two primary segments: branded generic formulations and Contract Development and Manufacturing Organisation (CDMO) services.
Financials
The company reported a 71.6% year-on-year (YoY) increase in net profit to Rs 14.45 crore in FY25 from Rs 8.42 crore in FY24. Revenue from operations rose 6% YoY to Rs 163.11 crore in FY25 from Rs 153.76 crore in FY24.
Disclaimer: Investments in initial public offerings are subject to market risks. Please consult with financial advisors and read red herring prospectus thoroughly before placing bids.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.